Los Angeles Capital Management
GLUE icon

Los Angeles Capital Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Los Angeles Capital Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.59K Sell
107
-25,224
-100% -$477K ﹤0.01% 2231
2026
Q1 		$417K Sell
25,331
-1,475
-6% -$28.2K ﹤0.01% 931
2025
Q4 		$349K Sell
26,806
-1,599
-6% -$21.5K ﹤0.01% 1029
2025
Q3 		$210K Buy
28,405
+8,618
+44% +$45.6K ﹤0.01% 1258
2025
Q2 		$89.2K Buy
+19,787
New +$88.3K ﹤0.01% 1262

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Los Angeles Capital Management's GLUE Position: Q2 2026 in Review

Los Angeles Capital Management reduced its Monte Rosa Therapeutics (GLUE) stake by 100% in Q2 2026, selling an estimated $477K and leaving 107 shares worth $2.59K. The position accounts for ﹤0.01% of the portfolio, ranked #2231.

Los Angeles Capital Management first reported a position in GLUE in Q2 2025 and has held it in 5 quarters since. The position peaked at $417K in Q1 2026. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Los Angeles Capital Management held 107 shares of Monte Rosa Therapeutics worth $2.59K as of Q2 2026.
  • Los Angeles Capital Management sold 25,224 Monte Rosa Therapeutics shares in Q2 2026, an estimated $477K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #2231 holding.
  • Los Angeles Capital Management first reported a position in Monte Rosa Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Los Angeles Capital Management's Monte Rosa Therapeutics position peaked at $417K in Q1 2026.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.